Table 1.
Baseline characteristics
| A: SMBG 1 day weekly (n = 22) |
B: SMBG 1 day every 2 weeks (n = 16) |
C: SMBG 1 day monthly (n = 20) |
|
|---|---|---|---|
| Gender (male) | 13 (59) | 8 (50) | 12 (60) |
| Age (years) | 67 ± 12 | 69 ± 9 | 65 ± 9 |
| Diabetes duration (year) | 11 (6, 15) | 8 (6, 13) | 13 (7, 17) |
| Duration SMBG (year) | 4 (2, 7) | 4 (3, 7) | 5 (4, 6) |
| HbA1c (mmol/mol) | 51 ± 4.7 | 52 ± 4.6 | 51 ± 5.6 |
| Fasting blood glucose (mmol/L) | 6.7 (6.0, 7.2) | 5.9 (4.8, 6.4) | 6.5 (5.4, 8.2) |
| Dose of insulin (units) | 22 (16) | 30 (22) | 20 (15) |
| Metformin | 21 (95%) | 14 (88%) | 16 (80%) |
| Tolbutamide | 4 (18%) | 4 (25%) | 7 (35%) |
| Gliclazide | 5 (23%) | 4 (25%) | 3 (15%) |
| Glimepiride | 3 (14%) | 2 (13%) | 3 (15%) |
| Body mass index (kg/m2) | 30 ± 4.1 | 30 ± 2.8 | 30 ± 3.6 |
| Systolic blood pressure (mmHg) | 141 ± 14 | 134 ± 11 | 133 ± 16 |
| Cholesterol/HDL ratio | 3.30 (2.9, 4.0) | 3.60 (3.3, 4.3) | 3.40 (2.8, 4.4) |
| Macrovascular complication (yes) | 5 (23) | 6 (38) | 5 (25) |
| Serum creatinine (μmol/L) | 71 (63) | 73 (60, 97) | 76 (63, 82) |
| Albumin creatinine ratio | 1.0 (0.3, 2.0) | 1.6 (0.99, 4.8) | 0.8 (0.5, 2.3) |
| Retinopathy (yes) | 0 (0) | 1 (6) | 3 (15) |
| Dose of insulin (units) | 22 (16, 29) | 30 (22, 36) | 20 (15, 39) |
| Smoking (yes) | 4 (18) | 2 (13) | 3 (15) |
| Alcohol use (yes) | 12 (55) | 6 (38) | 10 (50) |
Data are mean ± SD, n (% of known data) or median (P25, P75)